echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Breast Cancer Prognosm analysis after new complementary chemotherapy: Comparison of RCB and Neo-Bioscore scores

    Br J Cancer: Breast Cancer Prognosm analysis after new complementary chemotherapy: Comparison of RCB and Neo-Bioscore scores

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    New Assisted Chemotherapy (NAC) is currently suitable for systemic therapy with localized advanced breast cancer (BC), BC (triple negative and HER2-positive tumors) with poor prognostication, or early stage BC.
    previous studies have shown that patients with pathological complete remission (pCR) after NAC treatment have a more favorable long-term prognosis, especially in her2-positive and triple-negative BC (TNBC).
    As a result, prognostic scores such as RCB (Residual Cancer Burden Index), CPS (Clinical Pathology Score), CPS and EG (Estrogen-estory (E) Status and Nuclear Level (G)) and Neo-Bioscore have now been developed to classate BC patients into different prognostic risk categories after NAC treatment.
    study aims to compare the prognostic performance of RCB and Neo-Bioscore and explore whether adding relevant pathological variables can improve these ratings.
    the relationship between RCB and Neo-Bioscore scores and disease-free survival rates in population and pathological subtypes analyzed 750 patients with insanity breast cancer (BC) treated with NAC at the Curi Institute between 2002 and 2012.
    also compared Akaike Information Guidelines (AIC), C-Index, Correction Curves, Lymphatic Tube Immersion (LVI), and TILs levels before/after NAC in the global population and in the two score indices in each BC subsype.
    results showed that RCB and Neo-Bioscore scores were significantly associated with disease-free and overall survival rates in the global population and in patients with triple negative BC.
    in each BC subsype, RCB had the lowest AIC, corresponding to a better prognostic of the patient.
    the global population, the RCB's C index is poor, and Neo-Bioscore's C index is similar to the former.
    in the global population, the scores were better calibrated, but RCB performed better in the prognosis of each BC subsype, and the scores were less consistent.
    can improve the effectiveness of LVI and TIL indicators after adding them.
    the AIC, c-index, and calibration curves of RCB and neo-bioscore ratings, the results show that while RCB ratings and Neo-Bioscore ratings have similar prognoscation effects, RBCs perform better in BC subsyspes, especially in luminal and TNBC.
    , RCB may be better used in everyday clinical practice.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.